IL-18 ELISA Kit (Interleukin-18)

INTENDED USE

Human IL-18 ELISA kit is a method for detecting in vitro quantitative concentrations of interleukin-18 (IL-18) in human serum, plasma (EDTA, heparin), other biological fluids and tissue homogenates. This assay has a minimum detection limit of 9.375 pg/ml.

BACKGROUND

Interleukin-18 (IL-18) which is also referred to as interferon-gamma-inducing factor (IGIF) and is a non-glycosylated 24 kDa polypeptide which is known to lack any classical signal sequence. IL-18 is a cytokine which is member of the IL-1 superfamily and is primarily produced by macrophages and many other cells. It is synthesized as a bio-inactive pro-peptide which then undergoes proteolytic cleavage by either caspase enzymes or interleukin-1 beta converting enzyme (ICE) in order to generate a mature 18 kDa bioactive molecule.

IL-18 is a recently identified cytokine that has the ability to modulate both T helper type 1 (Th1) and Th2 responses. In order for it to carry out its function it needs to bind to the receptor and together with together with IL-12 it has the ability to induce cell-mediated immunity after an infection with microbial products such as lipopolysaccharide (LPS). Apart from its physiological role, IL-8 is found to induce many severe inflammatory reactions, this has led to a suggestion of possible roles in particular inflammatory disorders.

It has been implicated as a mediator of Hashimoto’s thyroiditis and found to increase Alzheimer’s disease-associated amyloid-beta production in many human neuron cells. IL-18 is also up regulated by interferon-gamma and is a potent pro-inflammatory cytokine with potential atherogenic properties. The biological effects of therapy include activation of T cells, monocytes, NK cells, production of IFN-gamma as well as other cytokines in vivo. It is found to act as a co-stimulatory cytokine and its optimal use as a cancer immune-therapy is possible with the combination of other immuno-stimulatory cytokines, monoclonal antibodies and vaccines.

CONTENT

All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.

• One 96-Well Plate: Pre-coated with anti-human IL-18 antibody.
• Standards: Concentrations 0, 15.625, 31.25, 62.5, 125, 250, 500, 1000 pg/ml.
• Sample/Standard Dilution Buffer.
• Biotinylated-labelled Antibody.
• Antibody Dilution Buffer.
• HRP-Streptavidin Conjugate (SABC).
• SABC Dilution Buffer.
• TMB Substrate.
• Wash Buffer (25x).
• Plate Sealer.
• Product Instructions.

SENSITIVITY

The minimum detection sensitivity level of interleukin-18 (IL-18) using this IL-18 ELISA kit was approximately 9.375 pg/ml. The dynamic range for this assay is 15.625 – 1,000 pg/ml.

ASSAY CHARACTERISTICS

– Specificity: Highly specific for IL-18, no cross reactivity or interference between IL-18 and analogues was detected.
– Recovery: Serum (90 – 105%), EDTA Plasma (88 – 102%), Heparin Plasma (95 – 104%).
– Linearity: Serum (98 – 102%), EDTA Plasma (82 – 101%), Heparin Plasma (85 – 99%).
– Precison Intra-Assay: CV < 8%.
– Precison Inter-Assay: CV < 10%.
– Stability: Less than 10%.

REFERENCES

1. Interleukin-18: recent advances. Curr Opin Hematol. (2004) 11 (6): 405-10. Review. Reddy P.
2. IL-18: a new player in immunotherapy for age-related macular degeneration? Expert Rev Clin Immunol. (2014) 10 (10): 1273-5. Review. Campbell M., et al.
3. The role of interleukin 18 in the metabolic syndrome. Cardiovasc Diabetol. (2010) 9: 11. Review. Trøseid M., et al.
4. Immunotherapeutic applications of IL-18. Immunotherapy. (2012) 4 (12): 1883-94. Review. Tsutsui H. and Nakanishi K.

ADDITIONAL INFORMATION

• Full Name: IL-18 ELISA Kit (Interleukin-18)
• Reactivity: Human
• Sample Type: Plasma (Heparin, EDTA), Tissue Homogenates, Serum, Biological Fluids
• Sensitivity: 9.375 pg/ml

OTHER RELATED ELISA KITS

• IL-8 ELISA Kit
• IL-16 ELISA Kit
• IL-10 ELISA Kit